Non-steroidal anti-inflammatory drugs and the risk of head and neck cancer: A case-control analysis

Menée au Royaume-Uni à partir de données portant sur 2 745 patients atteints d'un cancer de la tête et du cou diagnostiqué entre 1995 et 2013 et sur 16 470 témoins (âge inférieur à 90 ans), cette étude évalue l'association entre l'utilisation d'anti-inflammatoires non stéroïdiens (ibuprofène, aspirine, ...) et le risque de développer un cancer des voies aérodigestives supérieures

Résumé en anglais

Non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (aspirin) have been associated with a reduced risk for certain cancers. We explored the association between use of NSAIDs and the risk of head and neck cancer (HNC). We conducted a case-control analysis in the UK-based Clinical Practice Research Datalink (CPRD) among people below the age of 90 years with incident HNC between 1995 and 2013. Six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the HNC diagnosis. Other potential confounders including comorbidities and comedication were also evaluated, and we adjusted our final analyses for BMI, smoking and alcohol consumption. Our analyses included 2,745 HNC cases and 16,470 controls. Aspirin or NSAID use overall did not significantly change the HNC risk. However, patients with six or more prescriptions for ibuprofen were at a statistically significantly reduced risk for HNC (adjusted OR 0.59, 95% CI 0.37–0.94). The HNC risk tended to decrease with increasing cumulative exposure to ibuprofen, and to be more pronounced for cancer of the larynx. To conclude, in this large population-based observational study we found a decreased risk for HNC associated with regular use of ibuprofen.